Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence

European Urology

Volumn 47, Issue 5, 2005, Pages 653-659

  Grosse, Joachim ^a,b   Kramer, Guus ^a   Stöhrer, Manfred ^a  

^a BG UNFALLKLINIK MURNAU   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Aseptic intermittent catheterisation; Botulinum; Botulinum resistance; Detrusor injections; Neurogenic detrusor overactivity; Neurogenic urinary incontinence; Spinal cord injury

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLADDER CAPACITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMETRY; DETRUSOR DYSSYNERGIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MICTURITION REFLEX; MUSCLE WEAKNESS; NEUROGENIC BLADDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RELAPSE; STUDENT T TEST; SYMPTOM;

EID: 17144372940     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.11.009     Document Type: Article

References (42)

1. J.G. Blaivas Obstructive uropathy in the male Urol Clin North Am 23 1996 373 384
2. J.L. Hinson, and T.B. Boone Urodynamics and multiple sclerosis Urol Clin North Am 23 1996 475 481
3. V.W. Nitti, H. Adler, and A.J. Combs The role of urodynamics in the evaluation of voiding dysfunction in men after cerebrovascular accident J Urol 155 1996 263 266
4. H. Tanaka, H. Kakizaki, S. Kobayashi, T. Shibata, K. Ameda, and T. Koyanagi The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management J Urol 161 1999 929 932
5. P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, and U. Ulmsten Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
6. H. Madersbacher, J.J. Wyndaele, Y. Igawa, M. Chancellor, E. Chartier-Kastler, and A. Kovindha Conservative management in neuropatic urinary incontinence P. Abrams S. Khoury A. Wein Incontinence 2nd ed. 2002 Health Publication Ltd Plymouth 697 754
7. D. De Ridder, V. Chandiramani, P. Dasgupta, H. Van Poppel, L. Baert, and C.J. Fowler Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup J Urol 158 1997 2087 2092
8. M. de Seze, L. Wiart, P.A. Joseph, J.P. Dosque, J.M. Mazaux, and M. Barat Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions Neurourol Urodyn 17 1998 513 523
9. A. Giannantoni, S.M. Di Stasi, R.L. Stephen, P. Navarra, G. Scivoletto, and E. Mearini Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study J Urol 167 2002 1710 1714
10. P.C. Cartwright, and B.W. Snow Bladder autoaugmentation: early clinical experience J Urol 142 1989 505 508
11. M. Stöhrer, G. Kramer, M. Goepel, D. Lochner-Ernst, D. Kruse, and H. Rubben Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction Spinal Cord 35 1997 456 462
12. R.B. Filmer, and J.R. Spencer Malignancies in bladder augmentations and intestinal conduits J Urol 143 1990 671 678
13. H.D. Flood, S.J. Malhotra, H.E. O'Connell, M.J. Ritchey, D.A. Bloom, and E.J. McGuire Long-term results and complications using augmentation cystoplasty in reconstructive urology Neurourol Urodyn 14 1995 297 309
14. G.S. Brindley The first 500 patients with sacral anterior root stimulator implants: general description Paraplegia 32 1994 795 805
15. M. Stöhrer, B. Schurch, G. Kramer, D. Schmid, G. Gaul, and D. Hauri Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: A new alternative to medical and surgical procedures? Neurourol Urodyn 18 1999 401 402
16. B. Schurch, M. Stöhrer, G. Kramer, D.M. Schmid, G. Gaul, and D. Hauri Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692 697
17. K. Wohlfarth, H. Göschel, J. Frevert, R. Dengler, H. Bigalke, and Botulinum A toxins: units versus units Naunyn Schmiedebergs Arch Pharmacol 355 1997 335 340
18. J.S. Elston Blepharospasm and hemifacial spasm R.T. Johnson JW. Griffin Current therapy in neurologic disease 1993 Decker St. Louis 276 281
19. M.F. Brin, and A. Blitzer Botulinum toxin: dangerous terminology errors J R Soc Med 86 1993 493 494
20. Z. Nussgens, and P. Roggenkamper Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm Graefes Arch Clin Exp Ophthalmol 235 1997 197 199
21. C. Sampaio, J.J. Ferreira, F. Simoes, M.J. Rosas, M. Magalhaes, and A.P. Correia DYSPORT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1 Mov Disord 12 1997 1013 1018
22. T. Odergren, H. Hjaltason, S. Kaakkola, G. Solders, J. Hanko, and C. Fehling A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia J Neurol Neurosurg Psychiatry 64 1998 6 12
23. D. Ranoux, C. Gury, J. Fondarai, J.L. Mas, and M. Zuber Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia J Neurol Neurosurg Psychiatry 72 2002 459 462
24. M. Stöhrer, M. Goepel, A. Kondo, G. Kramer, H. Madersbacher, and R. Millard The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures Neurourol Urodyn 18 1999 139 158
25. M. Barinaga Secrets of secretion revealed Science 260 1993 487 489
26. T. Leippold, A. Reitz, and B. Schurch Botulinum toxin as a new therapy option for voiding disorders: current state of the art Eur Urol 44 2003 165 174
27. L.W. Duchen Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles J Neurol Neurosurg Psychiatry 33 1970 40 54
28. A.B. Scott Botulinum toxin injection of eye muscles to correct strabismus Trans Am Ophthalmol Soc 79 1981 734 770
29. J. Jankovic M. Hallet Therapy with botulinum toxin 1994 Marcel Dekker New York
30. J. Jankovic, and M. Brim Botulinum toxin: Historical perspective and potential new indications Muscle Nerve 20 Suppl 6 1997 129 145
31. P.J. Pasricha, W.J. Ravich, and A.N. Kalloo Botulinum toxin for achalasia Lancet 341 1993 244 245
32. M. Heckmann, A.O. Ceballos-Baumann, and G. Plewig Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating) N Engl J Med 344 2001 488 493
33. M. Naumann, M. Zellner, K.V. Toyka, and K. Reiners Treatment of gustatory sweating with botulinum toxin Ann Neurol. 42 1997 973 975
34. G.E. Borodic, M. Joseph, L. Fay, D. Cozzolino, and R.J. Ferrante Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread Head Neck. 12 1990 392 399
35. A. de Paiva, F.A. Meunier, J. Molgo, K.R. Aoki, and J.O. Dolly Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals Proc Natl Acad Sci USA 96 1999 3200 3205
36. A. Haferkamp, U. Krengel, A. Reitz, J. Grosse, G. Kramer, and S. Schumacher Are botulinum-A toxin injections into the detrusor of patients with neurogenic detrusor overactivity safe? Ultrastructural data of detrusor biopsies Neurourol Urodyn 22 2003 499 500
37. A.W. Biglan, R. Gonnering, L.B. Lockhart, B. Rabin, and F.H. Fuerste Absence of antibody production in patients treated with botulinum A toxin Am J Ophthalmol 101 1986 232 235
38. P. Greene, S. Fahn, and B. Diamond Development of resistance to botulinum toxin type A in patients with torticollis Mov Disord 9 1994 213 217
39. A.B. Scott Foreword J. Jankovic M. Hallet Therapy with botulinum toxin 1994 Marcel Dekker New York
40. A. Reitz, J. von Tobel, M. Stöhrer, G. Kramer, G. Del Popolo, and J. Pannek European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence Neurourol Urodyn 21 2002 427 428
41. G. Borodic, E. Johnson, M. Goodnough, and E. Schantz Botulinum toxin therapy, immunologic resistance, and problems with available materials Neurology 46 1996 26 29
42. J.J. Wyndaele, and S.A. Van Dromme Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity Spinal Cord 40 2002 599 600